This database contains 211 studies, archived under the term: "Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime"
Click here to filter this large number of results.
Cognitive change in donepezil treated patients with vascular or mixed dementia
Rockwood, Kenneth,
Mitnitski, Arnold,
Black, Sandra E.,
Richard, Matthew,
Defoy, Isabelle,
Vaspect study investigators
Background: vascular dementia (VaD) and mixed Alzheimer’s disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE) and other measures potentially usable in primary care.; Methods: A six-month, outcome measurement study. […]
Galantamine treatment in outpatients with mild Alzheimer’s disease
Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]
Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors
Pariente, A.,
Fourrier-Reglat, A.,
Bazin, F.,
Ducruet, T.,
Dartigues, J. F.,
Dragomir, A.,
Perreault, S.,
Moore, N.,
Moride, Y.
Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs).; Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (Régie de l’Assurance Maladie du […]
Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease
Okahara, Kazunori,
Ishida, Yasushi,
Hayashi, Yoshihito,
Inoue, Teruhiko,
Tsuruta, Kazuhito,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Yoshida, Kensei,
Noda, Shouji,
Tomita, Seiichiro,
Fujimoto, Masumi,
Hosomi, Jun,
Mitsuyama, Yoshio
Yokukansan (YKS) is used frequently against behavioral and psychological symptoms of dementia (BPSD) together with donepezil in patients with Alzheimer’s disease (AD). Here, we investigated the efficacy and safety of YKS in patients with AD in a non-blinded, randomized, parallel-group comparison study. Patients who had at least one symptom score of four or more on […]
The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease
Ohnishi, Takashi,
Sakiyama, Yojiro,
Okuri, Yuichi,
Kimura, Yuji,
Sugiyama, Nami,
Saito, Takayuki,
Takahashi, Masayoshi,
Kobayashi, Takumi
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo controlled trial to […]
The impact of supplemental macular carotenoids in Alzheimer’s disease: A randomized clinical trial
Nolan, John M.,
Loskutova, Ekaterina,
Howard, Alan,
Mulcahy, Riona,
Moran, Rachel,
Stack, Jim,
Bolger, Maggie,
Coen, Robert F.,
Dennison, Jessica,
Akuffo, Kwadwo Owusu,
Owens, Niamh,
Power, Rebecca,
Thurnham, David,
Beatty, Stephen
Background: Patients with Alzheimer’s disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and […]
Donepezil improves gait performance in older adults with mild Alzheimer’s disease: A phase II clinical trial
Montero-Odasso, Manuel,
Muir-Hunter, Susan W.,
Oteng-Amoako, Afua,
Gopaul, Karen,
Islam, Anam,
Borrie, Michael,
Wells, Jennie,
Speechley, Mark
Background: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer’s disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. Objective: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, […]